Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14279605 | 1.00 | HDAC8 (0.53) | HDAC8PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL5402857 | 0.95 | HDAC8 (0.48) | HDAC8PTPN1 | |
| SCHEMBL20720251 | 0.88 | PTPN1 (0.68) | HDAC8PTPN1 | |
| SCHEMBL29676960 | 0.88 | PTPN1 (0.68) | HDAC8PTPN1 | |
| SCHEMBL18793348 | 0.88 | PTPN1 (0.68) | HDAC8PTPN1 | |
| SCHEMBL19460727 | 0.86 | PTPN1 (0.54) | HDAC8PTPN1 | |
| SCHEMBL30254985 | 0.86 | PTPN1 (0.54) | HDAC8PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL864823 | 0.86 | PTPN1 (0.54) | HDAC8PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL29502321 | 0.86 | PTPN1 (0.54) | HDAC8PTPN1OPRD1OPRM1OPRK1 | |
| SCHEMBL29773931 | 0.86 | PTPN1 (0.54) | HDAC8PTPN1OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1469851-B1 | MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050075344-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
| EP-1469851-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040116699-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-06-17 | — | — | US | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075344-A1 | Melanocortin receptor agonists | MC4R, MC1R, MC5R | HDAC8 3936/4885PTPN1 1855/4885OPRD1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.